Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort

Cheng Yu Piao, Shin Ichi Fujioka, Yoshiaki Iwasaki, Kozo Fujio, Toshihiko Kaneyoshi, Yasuyuki Araki, Kuniaki Hashimoto, Tomonori Senoh, Ryo Terada, Tomohiro Nishida, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P = 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required. Copyright

Original languageEnglish
Pages (from-to)217-224
Number of pages8
JournalActa Medica Okayama
Volume59
Issue number5
Publication statusPublished - Oct 2005

    Fingerprint

Keywords

  • Child-Pugh score
  • Liver failure
  • Recurrence
  • Resistant mutant
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Piao, C. Y., Fujioka, S. I., Iwasaki, Y., Fujio, K., Kaneyoshi, T., Araki, Y., Hashimoto, K., Senoh, T., Terada, R., Nishida, T., Kobashi, H., Sakaguchi, K., & Shiratori, Y. (2005). Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Medica Okayama, 59(5), 217-224.